Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) shares were upgraded to "Hold" from "Sell" by Brean Murray, Carret & Co (BMC), given the sharp decline in valuation. Earlier this week, the U.S. health regulators placed a partial hold on further trials of the company's experimental hepatitis C treatment, IDX184, over safety concerns. [More...]